Welcome to our dedicated page for Elevation Oncolo news (Ticker: ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncolo stock.
About Elevation Oncology (Nasdaq: ELEV)
Elevation Oncology is an innovative biotechnology company dedicated to the discovery and development of selective cancer therapies aimed at addressing significant unmet medical needs in oncology. Based in Boston, the company specializes in leveraging antibody-drug conjugate (ADC) technology to create precision medicines targeting specific biomarkers associated with solid tumors. Its mission is to transform cancer treatment by delivering therapies tailored to the unique genomic profiles of patients.
Core Focus and Pipeline
Elevation Oncology’s lead candidate, EO-3021, is a clinical-stage ADC that targets Claudin 18.2, a protein overexpressed in various solid tumors, including gastric, gastroesophageal junction (GEJ), pancreatic, and esophageal cancers. EO-3021 is designed with advanced site-specific conjugation technology to optimize its safety and efficacy profile. The drug is currently being evaluated in a Phase 1 clinical trial for monotherapy and combination therapies, with promising initial data showing robust anti-tumor activity and minimal toxicity.
The company is also advancing EO-1022, a HER3-targeting ADC for cancers such as breast cancer, EGFR-mutant non-small cell lung cancer, and pancreatic cancer. EO-1022 leverages seribantumab, an anti-HER3 monoclonal antibody, combined with cutting-edge site-specific conjugation and payload delivery technologies.
Innovative Technology and Differentiation
Elevation Oncology employs state-of-the-art ADC technology, including site-specific conjugation to improve stability and minimize off-target effects. This approach enhances the therapeutic index of its ADCs, making them safer and more effective. The company’s focus on biomarker-driven therapies allows for precision targeting, ensuring that treatments are tailored to patient populations most likely to benefit.
EO-3021’s differentiated safety profile, including minimal hematological and peripheral neuropathy-related toxicities, makes it a potentially best-in-class ADC. Additionally, its combinability with other therapies, such as PD-1 and VEGFR2 inhibitors, positions it as a versatile treatment option across multiple lines of therapy.
Regulatory Milestones and Partnerships
EO-3021 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for advanced gastric and GEJ cancers expressing Claudin 18.2, underscoring its potential to address critical unmet needs. The company has also secured Orphan Drug Designation for gastric and pancreatic cancers, enhancing its regulatory pathway.
Elevation Oncology collaborates with leading pharmaceutical companies, including Lilly and GSK, to supply complementary therapies for combination trials. These partnerships strengthen its clinical development capabilities and expand its potential market reach.
Market Position and Competitive Landscape
Operating within the highly specialized field of ADCs, Elevation Oncology competes with established players like Daiichi Sankyo and AstraZeneca. However, its focus on Claudin 18.2 and HER3, combined with its advanced conjugation technology and biomarker-driven approach, provides a unique competitive edge. The company addresses a growing demand for targeted therapies in oncology, particularly for cancers with limited treatment options.
Commitment to Precision Medicine
Elevation Oncology’s approach aligns with the broader industry trend toward precision medicine, where treatments are tailored to the molecular characteristics of individual tumors. By focusing on clinically validated targets and leveraging cutting-edge ADC technology, the company aims to redefine the cancer treatment paradigm and improve patient outcomes.
Conclusion
With a robust pipeline, innovative technology, and strategic partnerships, Elevation Oncology is well-positioned to make a significant impact in the oncology landscape. Its dedication to addressing unmet medical needs through precision-targeted therapies underscores its potential to transform cancer care for patients worldwide.
Elevation Oncology (Nasdaq: ELEV), an innovative oncology company focused on developing selective cancer therapies for patients with solid tumors and significant unmet medical needs, has announced its participation in two upcoming investor conferences in March 2025.
The company will participate in:
- The TD Cowen 45th Annual Health Care Conference with a fireside chat on Tuesday, March 4, 2025 at 9:10 AM ET in Boston, MA
- The Leerink Global Biopharma Conference with a fireside chat on Tuesday, March 11, 2025 at 8:40 AM ET in Miami, FL
Live webcasts and replays of both fireside chats will be available on the Events page of Elevation Oncology's Investor Relations website at https://investors.elevationoncology.com.
Elevation Oncology (NASDAQ: ELEV) has announced significant progress in its cancer therapy programs. The company has initiated dosing in a Phase 1 clinical trial combining its Claudin 18.2 ADC EO-3021 with ramucirumab or dostarlimab for advanced gastric/GEJ cancer patients.
Initial monotherapy data from August 2024 showed promising results with a 42.8% confirmed overall response rate in a biomarker-enriched population, demonstrating competitive efficacy and a differentiated safety profile. The company is now focusing on first- and second-line treatment of advanced gastric/GEJ cancer.
Key upcoming milestones include additional monotherapy data from dose escalation and expansion cohorts in 1H 2025, initial combination cohort data in 4Q 2025 or 1Q 2026, and preclinical data presentation for HER3 ADC EO-1022 in 1H 2025. The company's current cash position is expected to fund operations into 2026.
Elevation Oncology (ELEV) has nominated EO-1022 as its HER3 ADC development candidate for treating HER3-expressing solid tumors. EO-1022 combines seribantumab, an anti-HER3 monoclonal antibody, with an MMAE payload using Synaffix's technology platform. The company has secured a global license agreement with Synaffix for their GlycoConnect®, HydraSpace®, and SYNstatin E™ technologies.
HER3 is expressed in various cancers including breast cancer, EGFR-mutant non-small cell lung cancer, and pancreatic cancer. The company plans to present preclinical data in 1H 2025 and file an IND application in 2026. Seribantumab has already demonstrated a well-tolerated safety profile in over 900 patients across multiple studies.
Elevation Oncology (ELEV) presented preclinical data demonstrating enhanced anti-tumor activity when combining their EO-3021 Claudin 18.2 antibody-drug conjugate (ADC) with VEGFR2 or PD-1 inhibitors. Key findings show:
- Combination with VEGFR2 inhibitor achieved 88.2% tumor growth inhibition vs 20.1% for EO-3021 alone
- Combination with PD-1 inhibitor reached 79.9% tumor growth inhibition vs 33.8% for EO-3021 alone
- 92% complete response rate in mice with PD-1 inhibitor combination vs 50% for EO-3021 monotherapy
The company plans to initiate combination trials with ramucirumab and dostarlimab in Q4 2024 for gastric/GEJ cancer patients, while continuing monotherapy trials with additional data expected in H1 2025.
Elevation Oncology (Nasdaq: ELEV) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Joseph J. Ferra, President and Chief Executive Officer, will engage in a fireside chat on Tuesday, December 3, 2024, at 8:30 a.m. ET. The company, which specializes in developing selective cancer therapies for patients with solid tumors, will provide a live webcast of the event, accessible through their Investor Relations website. A replay will also be available for those unable to attend the live presentation.
Elevation Oncology (ELEV) reported Q3 2024 financial results and progress on EO-3021, their Claudin 18.2 antibody-drug conjugate. Key highlights include a 42.8% confirmed objective response rate in Claudin 18.2-enriched gastric and GEJ cancer patients, with a favorable safety profile. The company received FDA Fast Track designation for EO-3021 and progressed to the dose expansion phase, with additional data expected in 1H 2025.
Financial results show cash position of $103.1 million, Q3 net loss of $12.9 million, and funding runway into 2026. R&D expenses increased to $9.4 million from $7.4 million year-over-year, while G&A expenses rose to $3.8 million from $3.5 million.
Elevation Oncology (Nasdaq: ELEV) announced that the FDA has granted Fast Track designation to EO-3021, a differentiated antibody drug conjugate, for treating advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer expressing Claudin 18.2 that has progressed after prior therapy. This designation is based on nonclinical and initial clinical data from the ongoing Phase 1 trial, which showed a confirmed overall response rate of 42.8% in a Claudin 18.2-enriched subset of GC/GEJ cancer patients. The company observed differentiated tolerability with minimal MMAE-associated toxicities. Elevation Oncology plans to report additional data in the first half of 2025 and initiate the combination portion of the study later this year.
Elevation Oncology (Nasdaq: ELEV), a company focused on developing selective cancer therapies for solid tumors, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Joseph J. Ferra will engage in a fireside chat on Tuesday, September 10, 2024, at 11:30 am ET.
The event will be accessible via a live webcast, with a replay available afterwards. Interested parties can view the webcast on the Events page of Elevation Oncology's Investor Relations website at https://investors.elevationoncology.com. This presentation offers an opportunity for investors and analysts to gain insights into the company's innovative approach to cancer treatment and its future prospects in the oncology sector.
Elevation Oncology (Nasdaq: ELEV) reported promising initial data from its Phase 1 clinical trial of EO-3021, showing a 42.8% confirmed ORR in Claudin 18.2-enriched gastric and GEJ cancer patients. The company is advancing to the dose expansion phase, with additional monotherapy data expected in 1H 2025. Elevation secured agreements with Lilly and GSK to evaluate EO-3021 in combination with ramucirumab and dostarlimab, respectively. The company remains on track to nominate a development candidate for its HER3-ADC program in 2H 2024.
Financially, Elevation reported $110.8 million in cash and equivalents as of June 30, 2024, up from $83.1 million at the end of 2023. Q2 2024 R&D expenses were $6.6 million, while G&A expenses were $4.4 million. The net loss for Q2 2024 was $10.5 million. The company expects its current cash position to fund operations into 2026.
Elevation Oncology (Nasdaq: ELEV) announced promising initial data from the Phase 1 clinical trial of EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2. Key highlights include:
1. 42.8% confirmed objective response rate in Claudin 18.2-enriched gastric and GEJ cancer subset.
2. Differentiated safety profile with minimal MMAE-associated toxicities.
3. Advancing to dose expansion phase; additional monotherapy data expected in 1H 2025.
4. Combination portion of Phase 1 trial to begin by year-end 2024.
The trial showed EO-3021 to be generally well-tolerated with no Grade 4 or 5 treatment-related adverse events. The company plans to explore doses of 2.0 mg/kg and 2.5 mg/kg IV Q3W in the expansion phase.
FAQ
What is the current stock price of Elevation Oncolo (ELEV)?
What is the market cap of Elevation Oncolo (ELEV)?
What does Elevation Oncology specialize in?
What are Elevation Oncology's key drug candidates?
What is EO-3021, and what makes it unique?
What regulatory designations has EO-3021 received?
How does Elevation Oncology differentiate itself in the competitive ADC market?
What partnerships support Elevation Oncology's clinical development?
What is the significance of Claudin 18.2 in cancer treatment?
What cancers are targeted by EO-1022?
What stage of development is EO-1022 currently in?
What is Elevation Oncology's long-term vision?
